RA0119

antibody from Oursmab

Targeting: CD47 IAP, MER6, OA3

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0119

Provider

Oursmab

Product name

Lemzoparlimab (Biosimilar Reference Antibody) (CD47)

Antibody type

Monoclonal

Description

Lemzoparlimab (also known as TJC4) is an investigational, humanized monoclonal antibody designed to selectively target CD47, a cell-surface protein often overexpressed by cancer cells as a "don't eat me" signal. Unlike earlier anti-CD47 antibodies, lemzoparlimab is engineered with a differentiated binding epitope to minimize red blood cell (RBC) binding and agglutination, thereby reducing the hematologic toxicity commonly associated with CD47 blockade. By blocking the interaction between CD47 and its receptor SIRP¦Á on macrophages, it aims to promote the phagocytosis and elimination of tumor cells. It is being developed primarily for the treatment of hematologic malignancies and solid tumors, both as monotherapy and in combination regimens.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.